Navigation Links
Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
Date:12/1/2008

Company Also Names Christopher Horvath, D.V.M., as Vice President of Preclinical Sciences and Marie Green, Ph.D., as Senior Program Executive

CAMBRIDGE, Mass., Dec. 1 /PRNewswire/ -- Taligen Therapeutics Inc. today expanded its Cambridge, Mass.-based executive team with the appointment of Jeffrey T. Walsh as chief business officer. The company also announced the additions of Christopher Horvath, D.V.M., as vice president of preclinical sciences and Marie Green, Ph.D., as senior program executive.

The executive appointments reflect the advancement of Taligen's corporate growth plan, which Taligen initiated in August with the hiring of Abbie Celniker, Ph.D., as chief executive officer. Taligen is focused on building its preclinical, CMC and clinical development operations in Cambridge while maintaining early research activities in the laboratory of Michael Holers, M.D., in Denver.

"I am pleased that Taligen has been able to attract the level of talent and experience that Mr. Walsh, Dr. Horvath and Dr. Green bring to the company," said Celniker. "We now have in place most of the key executives we believe are necessary to advance our lead clinical candidates through preclinical development to IND submission and to continue to advance Taligen's growth plan."

Walsh, will contribute to the development of the company's overall business strategy and oversee finance, legal, business development and general business operations. He has spent more than 20 years in leadership roles in the pharmaceutical and biotechnology industries with a focus on corporate finance, strategic planning and business development while at Inotek Pharmaceuticals Corp., Exact Sciences Corp., Pathogenesis Corp. (now part of Novartis), and SmithKline Beecham (now part of GlaxoSmithKline).

"I am looking forward to working with Dr. Celniker and the rest of the team that she has assembled as we build upon the potential ground breaking science coming out of Dr. Holers' laboratory," said Walsh. "Taligen's ability to develop multiple novel protein therapeutics targeting the alternative complement pathway and to specifically target them to sites of inflammation presents an exciting development opportunity and will afford us broad strategic latitude, including exploring substantial partnering opportunities. "

Dr. Horvath will drive the transition of basic research emerging from Dr. Holers' laboratory into the development phase. He will oversee pharmacology, PK/PD, toxicology, pathology and biological assays. He brings to Taligen extensive experience in the preclinical development and regulatory work required to file Investigational New Drug (IND) applications. Dr. Horvath has been responsible for non-clinical pharmacology and toxicology studies for a number of biologic compounds, including monoclonal antibody immunoconjugates and nucleic acids at Millennium Pharmaceuticals and Archemix Corp.

Dr. Green will lead Taligen's development project teams for the company's two most advanced clinical candidates, TT30 and TA106, across three potential indications: thrombotic microangiopathy, asthma and age-related macular degeneration. She has over 12 years of drug development experience first at Biogen-Idec and then at Millennium Pharmaceuticals. Most recently, Dr. Green has led global project teams for several product candidates in different phases of development at Millennium Pharmaceuticals.

About Taligen Therapeutics

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that are designed to modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver under Michael Holers, M.D., which closely collaborates with an international complement biology research community. For more information, visit HYPERLINK "http://www.taligentherapeutics.com/"www.taligentherapeutics.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to development of the Company's product candidates and potential advantages of the Company's technology and product candidates. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release.

    Media Contacts:

    Robert Flamm, Ph.D. or David Schull
    Russo Partners
    (212) 845-4226
    robert.flamm@russopartnersllc.com
    david.schull@russopartnersllc.com


'/>"/>
SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Precision Therapeutics Secures $43 Million in Venture Capital Funding
2. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
3. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
4. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
5. Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product
6. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
7. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
8. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
9. Cornerstone Therapeutics Announces New Board of Directors
10. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
11. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... check-in, a cloud-based self-service technology that runs on the Posiflex XT-series of touch ... 1076 during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is ...
(Date:2/20/2017)... Sunapee, NH (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software ... rapid growth of the company. The new location will triple the size of the ... location for the town of Sunapee, NH. , “We are excited to expand ...
(Date:2/20/2017)... Tampa, FL (PRWEB) , ... February 20, 2017 ... ... $20,000 gift from Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a ... ultrasonic waves. The gift was facilitated by the Pepin Family Foundation. , “We ...
(Date:2/19/2017)... ... 2017 , ... Orbita, Inc., a leading provider ... Healthwise ® at HIMSS 2017 to showcase a breakthrough in remote ... technology and services, will demonstrate a voice-powered knowedge assistant based on Orbita ...
(Date:2/18/2017)... ... , ... Park Cities Pet Sitter President, Joette White, has been featured on ... The episode, which was posted this week, features a 30-minute interview of White ... Cities Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... ORLANDO, Fla. , Feb. 20, 2017   ... will migrate its Amadeus precision medicine platform ... Health,s software currently manages over 110 million patient records ... approach to developing cloud-based, big data solutions built on ... Director of Healthcare and Life Sciences. "The AWS Cloud ...
(Date:2/20/2017)... Research and Markets has announced the addition of the ... report to their offering. ... An increasing number of patients suffering ... tension free repair procedures and increasing demand for minimally invasive ... market. However, Inconsistent reimbursement and the high cost of hernia ...
(Date:2/20/2017)... 20, 2017 According to a new market research ... powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End ... The market is projected to reach USD 52.37 Billion by 2021 from ... forecast period. Continue Reading ... ...
Breaking Medicine Technology: